Introduction and Objectives
To appraise the efficacy, safety and patient acceptability of vardenafil under real-life conditions in routine treatment of erectile dysfunction. The secondary aim was to evaluate the influence of the treatment on depressive symptomatology and self-esteem in men with erectile dysfunction.
Material and Methods
This was a prospective, open, uncontrolled, non-interventional, post-marketing, surveillance study. The observation period for each patient intakes over one month. For every subject investigator had to collect data at an initial and control follow-up visit. A patient questionnaire (PQ) together with CES-D and Rosenberg Scale questionnaires were used. 2543 patients were enrolled. As 2471 patients attended to initiating and at least one control visit they were included in intent-to-treat statstical analysis population.
Results
Overall erectile improvement was reported by 94.5% of the subjects. Effectiveness varied depending on severity, etiology and duration of the disorder as well as on the age of the patient. Penetration was possible in 96.8% of all sexual attempts documented in PQs. In 88.3% of endeavours the erection could be maintained long enough to complete intercourse. There was a significant improvement in frequency of depressive symptomatology during the observation in overall score of CES-D. Percentage of patients who presented with depressive symptoms decreased from 59.33% to 36.58% at initial vs. control visit respectively. Adverse drug reactions were were very rare – 0.45% patients. The most frequent were flushing and headache.
Conclusions
In this observational study Levitra was generally well tolerated and highly effective treatment of mild, moderate and severe ED of varying etiology.
Article info
Identification
Copyright
© 2009 European Association of Urology. Published by Elsevier Inc. All rights reserved.
